Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081315 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small-Cell Lung Carcinoma and Esophagitis, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT00081315 is a Phase 2 study of Non-Small-Cell Lung Carcinoma and Esophagitis that has completed, run by MedImmune. The registered enrollment target is 130 participants, below the 231-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00081315, a Phase 2 study of Non-Small-Cell Lung Carcinoma and Esophagitis, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.
Conditions Studied
Interventions
- DRUG Amifostine
Study Locations (20)
Florida
- Florida Wellcare Alliance - Inverness
- Florida Community Cancer Center - New Port Richey
- Ormand Memorial Cancer Center - Ormand Beach
- Sarasota Memorial Hospital - Sarasota
- University Community Hospital-Center for Cancer Care - Tampa
Maryland
- St. Agnes Health Care - Baltimore
- Center for Cancer & Blood Disorders - Bethesda
- Chesapeake Oncology-Hematology Associates - Glen Burnie
New York
- Long Island Jewish Medical Center - New Hyde Park
- Beth Israel Hospital - New York
- Upstate NY Cancer R&E Foundation - Rochester
California
- Cedars Sanai - Los Angeles
- Radiation Oncology Center - Sacramento
Pennsylvania
- Cancer Center of Upper Delaware Valley - Milford
- Montgomery Cancer Center - Norristown
Connecticut
- The Center for Cancer Care - Torrington
Kentucky
- University of Kentucky - Lexington
Missouri
- St. John's Medical Research - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081315
The ClinicalTrials.gov registry entry for NCT00081315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (44% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Amifostine is the first listed.
NCT00081315 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT00081315 about?
NCT00081315 is a clinical study titled "Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer". The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.
What is the current status of trial NCT00081315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2003-11. Estimated completion is 2006-08.
What conditions does trial NCT00081315 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma, Esophagitis, Pneumonitis.
What interventions are being tested in trial NCT00081315?
The interventions under investigation include: Amifostine (DRUG).
Who is sponsoring clinical trial NCT00081315?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081315 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.